LTG-305
/ Latigo Biotherap
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
July 07, 2025
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=112 | Completed | Sponsor: Latigo Biotherapeutics | Recruiting ➔ Completed | Trial completion date: Sep 2025 ➔ Jun 2025
Trial completion • Trial completion date
May 22, 2025
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Latigo Biotherapeutics | Trial completion date: Mar 2025 ➔ Sep 2025 | Trial primary completion date: Mar 2025 ➔ Aug 2025
Trial completion date • Trial primary completion date
November 26, 2024
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=120 | Recruiting | Sponsor: Latigo Biotherapeutics | N=80 ➔ 120
Enrollment change
November 20, 2024
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=80 | Recruiting | Sponsor: Latigo Biotherapeutics | Not yet recruiting ➔ Recruiting
Enrollment open
August 15, 2024
A Phase 1 Single and Multiple Ascending Dose Study of LTG-305 Administered Orally in Healthy Participants
(clinicaltrials.gov)
- P1 | N=80 | Not yet recruiting | Sponsor: Latigo Biotherapeutics
New P1 trial
1 to 5
Of
5
Go to page
1